Suppr超能文献

肺细胞学中的程序性死亡受体配体1(PD-L1):标准化之路

PD-L1 in Lung Cytology: The Path for Standardization.

作者信息

Mansour Mohammed S I, Acanfora Gennaro, Troncone Giancarlo, Brunnström Hans, Vigliar Elena

机构信息

Department of Pathology and Cytology, Halland Hospital Halmstad, Halmstad, Sweden.

Division of Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

出版信息

Acta Cytol. 2025 May 14:1-16. doi: 10.1159/000546275.

Abstract

BACKGROUND

The advent of programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors has revolutionized lung cancer treatment, necessitating accurate PD-L1 immunohistochemical (IHC) assessment. While standardized for formalin-fixed paraffin-embedded histological samples, PD-L1 testing on cytology remains challenging. This review aims to address the complexities of PD-L1 IHC in cytology, focusing on validation guidelines, quality assessment, cytohistological correlation, and interobserver variability.

SUMMARY

This review synthesizes current guidelines and research on PD-L1 IHC in cytology; in particular, recent College of American Pathologists (CAP) guidelines emphasize the necessity for rigorous validation, particularly for non-formalin-fixed specimens. As far as cytohistological concordance studies are concerned, the review of 48 original articles revealed significant variability in PD-L1 expression, with concordance rates ranging from 54 to 100% at the 1% cutoff and 82-100% at the 50% cutoff. Finally, interobserver variability, particularly in the 1-49% PD-L1 expression range, further complicates accurate assessment. The review also discusses the challenges associated with quality assessment in cytology, including the lack of standardized control materials and external quality assessment (EQA) programs specifically tailored for cytological samples.

KEY MESSAGES

PD-L1 testing in cytology is feasible but faces substantial challenges compared to histological specimens. Validation of PD-L1 IHC protocols for cytological preparations, especially non-formalin-fixed samples, is essential. Concordance between cytological and histological PD-L1 expression is variable, highlighting the need for caution in interpretation. Interobserver variability, particularly in cases with intermediate PD-L1 expression (1-49%), affects diagnostic reproducibility. The development of standardized quality control materials and EQA programs for cytology is urgently needed to support consistent and reliable PD-L1 testing.

摘要

背景

程序性细胞死亡蛋白1/程序性死亡配体1(PD-1/PD-L1)抑制剂的出现彻底改变了肺癌治疗方式,这就需要对PD-L1进行准确的免疫组织化学(IHC)评估。虽然PD-L1检测在福尔马林固定石蜡包埋的组织学样本中已实现标准化,但在细胞学样本上进行PD-L1检测仍具有挑战性。本综述旨在探讨细胞学中PD-L1免疫组化的复杂性,重点关注验证指南、质量评估、细胞组织学相关性和观察者间变异性。

总结

本综述综合了当前关于细胞学中PD-L1免疫组化的指南和研究;特别是,美国病理学家学会(CAP)最近的指南强调了严格验证的必要性,尤其是对于非福尔马林固定的标本。就细胞组织学一致性研究而言,对48篇原创文章的综述显示,PD-L1表达存在显著差异,在1%临界值时一致性率为54%至100%,在50%临界值时为82%至100%。最后,观察者间变异性,特别是在PD-L1表达范围为1%至49%时,进一步增加了准确评估的复杂性。该综述还讨论了细胞学质量评估面临的挑战,包括缺乏标准化对照材料和专门针对细胞学样本的外部质量评估(EQA)计划。

关键信息

细胞学中的PD-L1检测是可行的,但与组织学标本相比面临重大挑战。对细胞学制剂,尤其是非福尔马林固定样本的PD-L1免疫组化方案进行验证至关重要。细胞学和组织学PD-L1表达之间的一致性各不相同,这突出了在解释时需要谨慎。观察者间变异性,特别是在PD-L1表达为中等水平(1%至49%)的病例中,会影响诊断的可重复性。迫切需要开发用于细胞学的标准化质量控制材料和EQA计划,以支持一致且可靠的PD-L1检测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验